282. 先天性赤血球形成異常性貧血 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 4 / 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 10
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
Analysis OF genetic modifiers
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Disease phenotyping
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Luspatercept
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Omeprazole
Soroka University Medical Center
2013 Phase 4 NCT01795794 -
Reblozyl
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Zoledronic acid
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 1/Phase 2 NCT07471516 China
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Disease phenotyping
Hospital Universitari Vall d'Hebron Research Institute
2020 - NCT07206095 Spain
Luspatercept
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Omeprazole
Soroka University Medical Center
2013 Phase 4 NCT01795794 -
Reblozyl
FOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia
2023 Phase 2 EUCTR2020-005736-30-IT Italy
Zoledronic acid
Institute of Hematology & Blood Diseases Hospital, China
2026 Phase 1/Phase 2 NCT07471516 China
